BNY · sample dossier
Bank of New York Mellon Corporation
62/100
OutdatedGenerated Oct 10, 2026 · 10:00 AM UTC · 3 hours ago
This copy is frozen (Oct 10). Sign in to run the same work — filings, valuation, bull and bear, sources — on any US stock or ETF, in about 90 seconds.
Run a fresh dossierBNY
EquityBank of New York Mellon CorporationXNYS
Decision context
HOLD
74% convictionThe latest quarter is more than 100 days old, so this stays a Hold.
A mixed picture — no strong reason to buy or sell right now.
The stock trades 16.8% above our estimate.
Current price
$142.71
Estimated value range
$107.76 – $120.26
Gap vs AlphaDog estimate
-16.8%
Narrow evidence — range rests on a single usable method.
The price is above our estimate, providing little valuation support.
Market context
Price
Price when available
Pick how far back the chart looks
1 month
-12.2%
3 months
-5.7%
6 months
+11.9%
1 year
+34.6%
Financial trajectory
Executive summary & thesis
Bank of New York Mellon Corporation is an institutional custodian with a market capitalization of $96.83B, trading at a price of $142.71 and a P/E multiple of 16.65.
- Latest quarter YoY EPS growth reached 26.9% for the quarter ended June 30, 2026, demonstrating accelerating operational earnings power.
- Assets under custody and/or administration expanded to $62.6 trillion as of June 30, 2026, reinforcing global servicing scale.
- Net margin reached 29.4% alongside a pre-tax operating margin of 39.8% for the quarter ended June 30, 2026.
- Shares suffered a -12.2% 1-month drawdown and trade below their 50-day moving average, signaling deteriorating near-term technical support.
- BNY trades at a P/E multiple of 16.65, representing a premium over peer money-center banks JPM at 14.3 and BAC at 12.5.
- Insider activity recorded net sales of -$5.86M over the trailing 3 months, reflecting institutional liquidity exits.
Things to keep in mind
- 1Base target implies 16.8% downsideView source
- 2P/E 16.7xView source
- 3Shares suffered a -12.2% 1-month drawdown and trade below their 50-day moving average, signaling deteriorating near-term technical support.View source
What to watch next
Factor profile
Value-sensitive setup
| Factor | Score |
|---|---|
| Quality | 43 out of 100 (Neutral). Business health — profits, returns, and consistency. Higher means a more durable company. |
| Growth | 74 out of 100 (Strong). How fast sales and earnings are rising. Higher means the business is expanding faster. |
| Value | 84 out of 100 (Elite). How cheap the stock looks for what you get. Higher means a more attractive price. |
| Safety | 55 out of 100 (Neutral). Balance-sheet cushion and fewer red flags. Higher means less risk of a nasty surprise. |
| Momentum | 61 out of 100 (Neutral). Recent share-price trend. Higher means buyers have been in control lately. |
Another way to look at it
A calmer look at both sides of the BNY story
The consensus Buy verdict rests entirely on trailing earnings momentum—specifically sequential EPS climbing from $1.88 to $2.45 and a 29.4% net margin—while ignoring that BNY trades at a rich P/E multiple of 16.65 compared to peers JPM at 14.3, BAC at 12.5, and WFC at 11.9.
This peer valuation premium leaves zero margin for safety given that the price-to-book ratio stands at 2.43 against a modest 1.3% ROA. The consensus and debate summarily dismiss the stock's -12.2% 1-month retreat and break below the 50-day moving average, even as insiders dumped a net -$5.86M in stock across 10 sales over the trailing 3 months. Furthermore, top-line revenue growth YoY and balance-sheet Debt/Equity are entirely missing from disclosures, concealing whether the 26.9% EPS growth is operational or driven by financial engineering. Extrapolating quarterly fee revenues above the $4,252M recorded on June 30, 2026 into future multiple expansion ignores the -5.7% 3-month tape contraction and represents late-cycle complacency.
Balance sheet leverage cannot be evaluated because Debt/Equity is not publicly available, leaving structural solvency risk unexamined while the stock trades at 2.43 P/B.
Organic top-line trajectory is unknown because revenue growth YoY is omitted from reporting, preventing verification of whether 26.9% EPS growth stems from fee expansion or one-off items.
Regulatory disclosures cited from early 2026 are older than 90 days relative to the 2026-10-10 review date, creating reliance on stale compliance data.
BNY trades at 16.65 P/E, representing an unjustified 16% to 40% valuation premium over commercial banking peers JPM at 14.3, BAC at 12.5, and WFC at 11.9 despite generating an unexceptional 1.3% ROA.
Consensus models continuous multiple expansion based on maintaining quarterly fee revenue above $4,252M, ignoring that market downturns directly compress the $62.6 trillion AUC/A fee base.
Extrapolating four quarters of sequential EPS growth from $1.88 to $2.45 disregards that 29.4% net margin represents a peak cyclical level vulnerable to mean reversion.
Latest quarter YoY EPS growth decelerates below 26.9%.
Net margin contracts below 29.4%.
Cash after investing
Cash-flow details are thin for BNY — check the Financials tab when you can.
- Latest quarter YoY EPS growth decelerates below 26.9%.
- Net margin contracts below 29.4%.
Monitor these triggers
3 checkpoints before the next earnings print
Latest quarter YoY EPS growth (current baseline: 26.9%)
ROA drops below 1.3%.
Net margin contracts below 29.4%.
Latest quarter YoY EPS growth falls below 26.9%.
For learning and research only — not investment advice. AlphaDog doesn’t hold stocks and isn’t your financial advisor.
Run the next one yourself.
You just read a full BNY dossier — scored verdict, valuation, and both sides, with sources. Sign in to run that on a name you hold, on current filings. A free account includes 10 credits a week, 1 per fresh run.